STOCKS TELEGRAPH

Category: Mid Day Movers

  • Miromatrix (MIRO) Stock Is Surging Following A Takeover Bid

    Miromatrix (MIRO) Stock Is Surging Following A Takeover Bid

    Miromatrix Medical Inc. (NASDAQ: MIRO) shares have surged dramatically in the current trading session. At the last check, Miromatrix’s stock has experienced a remarkable upswing of 226.72%, reaching a trading price of $3.30. Additionally, the stock of MIRO is demonstrating a robust performance on this Monday, marked by a substantial increase in trading activity.

    This phenomenon is evident as approximately 2 million shares of the company have changed hands during the morning trading session. Such trading volume significantly surpasses the typical daily trading volume for Miromatrix, which stands at about 19.5K shares.

    In a noteworthy development, Miromatrix (MIRO) has officially announced a binding agreement with United Therapeutics Corporation, outlining United Therapeutics’ intention to acquire Miromatrix. This acquisition is poised to expand the array of organ manufacturing initiatives under United Therapeutics’ umbrella, which encompasses ex-vivo lung perfusion, xenotransplantation, 3-D bioprinting, and regenerative medicine approaches.

    The overarching goal of these endeavors is to establish a limitless supply of viable transplantable organs. In line with this agreement, United Therapeutics will initiate a tender offer to procure all outstanding MIRO shares. The cash purchase price per Miromatrix share at closing is set at $3.25, resulting in a total transaction value of approximately $91 million.

    Moreover, an additional $1.75 per MIRO share in cash will be awarded upon the attainment of a significant clinical development milestone, which is tied to Miromatrix’s pioneering mirokidney product. This fully-implantable kidney innovation is anticipated to reach a development stage milestone by December 31, 2025.

    This transaction is exempt from any financial prerequisites and is anticipated to be concluded during the final quarter of 2023, subject to the customary closing conditions. These conditions encompass the requirement for a majority of outstanding Miromatrix common stock shares to be tendered.

    Following the successful completion of the tender offer, any remaining Miromatrix shares will be acquired by United Therapeutics in a subsequent merger, with the same terms as the tender offer.

    The purchase price to be paid at closing represents a substantial premium of around 170% over the 30-day volume-weighted average trading price of Miromatrix’s common stock, calculated up to October 27, 2023, the day prior to the transaction announcement. The board of directors at Miromatrix unanimously recommends that the company’s shareholders participate in the tender offer.

    This transaction provides MIRO shareholders with a notable premium and grants them the opportunity to partake in the potential benefits of this collaboration, all while expediting the advancement of Miromatrix’s product pipeline.

  • Tourmaline (TRML) Is Surging On The Charts Today, Why?

    Tourmaline (TRML) Is Surging On The Charts Today, Why?

    Tourmaline Bio, Inc. (NASDAQ: TRML) shares are experiencing a notable uptick in value this morning, notwithstanding the absence of any official announcements from the biotechnology firm. As of the last check, Tourmaline stock has advanced by 5.07% to reach a valuation of $14.71 on the charts. Therefore, recent developments within Tourmaline may provide us with enhanced insights into the trajectory of TRML shares.

    Tourmaline (TRML) has recently culminated its previously disclosed merger with Talaris Therapeutics. The resulting amalgamated entity has commenced operations under the banner of Tourmaline Bio, Inc., and it began trading on the Nasdaq Global Market as of October 20, 2023, under the present ticker symbol.

    Simultaneous to this merger, Tourmaline successfully completed a private placement worth $75 million, involving a consortium of both fresh and pre-existing institutional investors in the life sciences sector. Following these financial transactions, TRML’s coffers, including cash reserves, liquid assets, and investments, were estimated at approximately $218 million before the finalization of transaction-related expenditures. This financial position is anticipated to fund operational activities through the year 2026.

    In conjunction with the merger’s closing, Talaris executed a 1-for-10 reverse stock split of its common shares and disbursed a special cash dividend to Talaris shareholders who were recorded as of October 16, 2023, and who retained their eligible shares of Talaris until the market opened on October 20, 2023, which marked the ex-dividend date for the aforementioned special cash dividend.

    Subsequent to the reverse stock split and the formalization of the merger, the total number of outstanding common shares for the combined entity reached approximately 20,336,773. Former Talaris stockholders retained roughly 21.9% ownership, while previous Tourmaline stockholders held about 78.1% of the overall common stock issued by the merged company.

    Tourmaline’s current strategic focus revolves around its flagship program, TOUR006, an anti-IL-6 antibody characterized by distinctive attributes such as a pronounced affinity for IL-6 and an inherently extended half-life. TOUR006 is currently in the preclinical testing phase.

    Additionally, Tourmaline has laid out plans to commence a Phase 2 clinical trial for TOUR006 in the context of atherosclerotic cardiovascular disease (ASCVD) in 2024. ASCVD remains a pervasive global cause of mortality, despite the widespread availability of oral therapeutic options.

    Notably, IL-6 has surfaced as a promising therapeutic target for addressing ASCVD, as supported by over two decades of clinical, genetic, and experimental research. Furthermore, Tourmaline intends to explore supplementary prospects for TOUR006 in addressing other indications across a wide spectrum of diseases where IL-6 inhibition has garnered validation.

  • Why ABVC BioPharma Stock Is On The Rise Today

    Why ABVC BioPharma Stock Is On The Rise Today

    ABVC BioPharma Inc. (NASDAQ: ABVC) is experiencing a remarkable surge in its current trading session. As of the last check, ABVC BioPharma’s stock has soared by an impressive 270.25%, reaching a valuation of $3.15 per share. This substantial upswing in ABVC’s stock price can be directly attributed to a significant global licensing endeavor.

    ABVC BioPharma (ABVC) has formally entered into a legally binding term sheet establishing a comprehensive, multi-year global licensing pact with AiBtl BioPharma, denoted as AiBtl. The agreement encompasses ABVC’s Central Nervous System (CNS) pharmaceuticals, specifically tailored for treating Major Depressive Disorder (MDD) and Attention Deficit Hyperactivity Disorder (ADHD).

    The proposed licensing arrangement will encompass clinical trial oversight, registration, manufacturing, supply, and distribution rights for the Licensed Products. The Licensed Products related to MDD and ADHD, both held by ABVC and its subsidiary BioLite, Inc., have been assessed at an impressive valuation of $667 million by an impartial third-party evaluation.

    ABVC and AiBtl are unequivocally committed to fostering a global synergy in the development of these Licensed Products. Furthermore, they are dedicated to reinforcing their collaboration in novel drug development and business strategies, including technological innovation, interoperability, and standards advancement.

    Under the binding term sheet, ABVC’s licensing revenues, pertaining to both ABVC and its subsidiary BioLite, Inc., will comprise 46 million shares of AiBtl stock (representing 57% ownership of AiBtl) and milestone cash disbursements amounting to $7 million, coupled with a 5% royalty on net sales, capped at $200 million, post-launch.

    An essential facet of AiBtl’s collaborative initiative is the fusion of health and resort industries. Moreover, the partnership aims to leverage revenue streams emanating from land leases within the Asia Economic Development Zone.

    AiBtl possesses considerable expertise in global business expansion, and this affiliation with ABVC will facilitate the establishment of alliances with international pharmaceutical entities for the advancement of the Licensed Products and the subsequent introduction of CNS medications into the market.

    In tandem, this association will allow ABVC BioPharma to maintain its focus on launching other proprietary patented products, such as ophthalmological medical devices like Vitargus and oncology drugs, into the global market.

  • Nuvve (NVVE) Stock Is Skyrocketing This Morning, Why?

    Nuvve (NVVE) Stock Is Skyrocketing This Morning, Why?

    Nuvve Holding Corp. (NASDAQ: NVVE) has experienced a remarkable surge of 105.07%, with its stock price reaching $0.3039 in the most recent trading session as of the last check. Notably, Nuvve’s trading volume has exceeded an impressive 63 million shares, far surpassing its typical weekly average of 0.7 million shares. This notable upswing in the value of NVVE shares can be attributed to the company’s strategic all-electric move.

    In a significant announcement today, Nuvve (NVVE) unveiled its collaboration with Blue Bird Corporation (Nasdaq: BLBD), signifying the replacement of their conventional diesel fleet. Nuvve has successfully transitioned the fleet of the Martinsville Independent School District (ISD) to a fleet consisting of five Blue Bird Vision electric buses. This transformation also encompassed the replacement of five Nuvve Level II chargers and the incorporation of the innovative AI-driven Nuvve FleetBox 2.0 charge management software.

    Of particular note is that the Martinsville ISD now proudly holds the distinction of being the first school district in Texas to boast an entirely electric school bus fleet. This achievement aligns with the objectives of the Texas Electric School Bus Project, a nonprofit organization dedicated to tracking and promoting school transportation electrification within the state.

    The Blue Bird Vision electric buses, which are emissions-free, have a maximum passenger capacity of 71 students and can cover up to 120 miles on a single charge. Thanks to Nuvve’s cutting-edge battery charging infrastructure, these buses require only a modest portion of the day to achieve a full recharge.

    Principal Keith Kimbrough of Martinsville ISD played a pivotal role in securing a substantial $1.58 million Clean School Bus grant from the U.S. Environmental Protection Agency in October 2022, which provided crucial financial support for this transformative project.

    Additionally, partnerships with Rush Truck Centers as the dealer, Blue Bird for the fleet, and Nuvve K-12 for consultation and the provision of suitable chargers and software have been instrumental in making this vision a reality, effectively catering to the district’s transportation needs and daily charging requirements.

    Throughout this electrification endeavor, the Nuvve K-12 team and its partners have offered unwavering guidance and comprehensive support to the Martinsville Independent School District, thereby marking an important milestone for NVVE and the company’s first installation in the state of Texas.

  • Why Is Twin Ridge (TRCA) Gaining Traction Today?

    Why Is Twin Ridge (TRCA) Gaining Traction Today?

    Twin Ridge Capital Acquisition Corp. (NYSE: TRCA) witnessed a remarkable surge of 47.83%, with its stock currently standing at $9.86 at last check. This notable upswing in Twin Ridge’s stock value, while seemingly unrelated to any prominent news, can be attributed to recent strategic developments.

    Twin Ridge has recently declared that the scheme of arrangement concerning its merger with Carbon Revolution has gained legal validity. Consequently, the quotation of Carbon Revolution shares on the ASX was suspended at the close of business last Thursday. Carbon Revolution Limited holds the distinction of being a Tier 1 original equipment manufacturer (OEM) supplier, and it stands as a premier global producer of state-of-the-art lightweight carbon fiber wheels.

    This development followed the unanimous approval of the scheme of arrangement by Carbon Revolution shareholders on October 15, 2023, as well as the formal endorsement of the scheme by the Federal Court of Australia on Wednesday. Twin Ridge Capital Acquisition Corp. shareholders had previously given their endorsement to the business amalgamation on October 12, 2023.

    The execution of the scheme of arrangement, slated for October 31, 2023, is contingent on the fulfillment of requisite conditions. Under this arrangement, Carbon Revolution plc is anticipated to emerge as the parent company of Carbon Revolution and commence trading on the Nasdaq Capital Market, utilizing the ticker symbol “CREV,” starting from October 30, 2023.

    The attainment of these momentous milestones is set to usher Carbon Revolution into a new phase as a publicly traded entity in the United States. Twin Ridge firmly believes that Carbon Revolution is exceptionally well-situated to leverage the burgeoning demand for its groundbreaking efficiency technology, particularly within the electric vehicle and emerging mobility sector.

    Twin Ridge has consistently extended its support to Carbon Revolution in its journey towards becoming a publicly traded company in the United States. This confidence in Carbon Revolution’s prospects is reinforced by its collaboration with six global OEMs, including distinguished names such as Ford Motor Company, General Motors, Renault, Ferrari N.V., and Jaguar Land Rover.

    In connection with the upcoming implementation, Carbon Revolution is expected to have access to a substantial capital pool amounting to US$95 million. This encompasses a sum of US$35 million from the structured equity facility, which can reach up to US$110 million, involving two fund vehicles linked with Orion Infrastructure Capital, as well as a US$60 million committed equity facility. The release of the remaining US$75 million under the structured equity facility is contingent upon the company’s achievement of specified future growth milestones.

  • What Drove Treasure Global (TGL) Stock Higher?

    What Drove Treasure Global (TGL) Stock Higher?

    Treasure Global Inc. (NASDAQ: TGL) shares have seen a remarkable surge, rising by 17.81% to $0.47 in the current trading session Wednesday. Within today’s trading activity, a substantial volume of more than 1.45 million shares of Treasure Global changed ownership. This surge in TGL stock price coincides with a noteworthy declaration of ownership interest by an offshore entity.

    In a disclosure to the Securities and Exchange Commission (SEC), it has been filed that AI Lab Martech Sdn Bhd, a privately held corporation domiciled in Malaysia, now possesses over 10% ownership in Treasure Global. AI Lab currently holds a total of 2,943,021 TGL shares, which translates to a 14.49% stake in TGL based on the 20,317,579 shares outstanding as of September 25, 2023.

    Furthermore, Treasure Global has embarked on a transformative journey into the realm of e-commerce. This paradigm shift was achieved through the introduction of an artificial intelligence (AI) robot tailored for conducting extended-hour live commerce sessions on the TikTok platform. This groundbreaking development not only propels Treasure Global’s subsidiary, ZCITY, to unprecedented heights but also heralds a revolution in the way businesses engage with their audience on TikTok, the world’s most bustling live commerce hub.

    The advent of TikTok Live Commerce represents an unparalleled opportunity for Treasure Global’s subsidiary to diversify its revenue streams and present its products in a fresh, engaging manner. With the acquisition of cutting-edge technology from Tencent, ZCITY has taken a significant stride towards crafting its very own live commerce robot, adept at seamless interaction with viewers through a chatbox interface.

    ZCITY’s live commerce robot, driven by advanced AI technology, stands as a pioneering model, showcasing products and services in real-time on the TikTok platform. This innovative marketing approach not only captivates the TikTok community but also cultivates a dynamic and immersive shopping experience for the viewers.

    This watershed moment for Treasure Global and its subsidiary, ZCITY, with its innovative AI robot, promises to redefine the e-commerce landscape within TikTok. Furthermore, it signifies Treasure Global’s unwavering commitment to innovation and technological advancement, which continues to mold the future of e-commerce and enhance the way businesses and customers connect in the digital era.

  • Following The Validation Of Trial Results, BioXcel (BTAI) Stock Is Rising

    Following The Validation Of Trial Results, BioXcel (BTAI) Stock Is Rising

    BioXcel Therapeutics, Inc. (NASDAQ: BTAI) shares have exhibited a notable surge of 23.08%, reaching $2.88 in the present trading session, as per the most recent data.

    The BioXcel stock was trading in a range spanned from $2.83 to $3.35 during today’s market activity, with a substantial trading volume of over 50 million shares.

    The catalyst for this morning’s ascent in BTAI stock can be attributed to a positive evaluation by an external party concerning the results of its clinical trial.

    Today, BioXcel (BTAI) unveiled encouraging outcomes stemming from an impartial third-party assessment of data from a specific site within its TRANQUILITY II Phase 3 trial.

    This audit, conducted by a well-respected regulatory and quality consulting firm, involved a thorough scrutiny of records pertaining to more than 50% of the trial’s participants at that specific site.

    The primary objectives of the audit encompassed the detection of any potential irregularities, misconduct, or fraudulent activities and an assessment of the integrity and reliability of the data pertaining to eligibility, safety, and efficacy.

    The sample size employed in this assessment ensures a 95% confidence level in the representativeness of the data reviewed.

    Following a comprehensive examination, the team of auditors did not uncover any elements that could compromise the reliability or integrity of the data, nor did they unearth any indications of further misconduct or fraud.

    Based on these findings, BioXcel has the belief that the positive and statistically significant data from the TRANQUILITY II trial, as announced in June 2023, could potentially serve as a basis for a supplemental new drug application (sNDA) for BXCL501, aimed at the acute treatment of agitation associated with dementia in probable Alzheimer’s disease.

    BioXcel is of the opinion that the results of this audit, conducted by a respected and independent entity, affirm the trustworthiness of the data originating from the specific site under scrutiny.

    Furthermore, these results enrich the body of clinical evidence that the company intends to incorporate into its sNDA submission.

    Notably, BTAI has recently conducted a Type B/Breakthrough meeting with the FDA to discuss the development plans for BXCL501 concerning the acute treatment of agitation in the context of dementia related to probable Alzheimer’s disease.

    BioXcel anticipates the receipt of the FDA meeting minutes in the first half of November and intends to provide an update on the subsequent phases of the TRANQUILITY program and the potential sNDA in its forthcoming third-quarter financial report.

  • LianBio (LIAN) Stock Is On The Rise Today: What’s Driving It?

    LianBio (LIAN) Stock Is On The Rise Today: What’s Driving It?

    LianBio (NASDAQ: LIAN) stock has exhibited a notable ascent on the financial charts during the early trading hours. In the morning session, the LianBio stock recorded a significant surge of 79.14%, reaching a value of $2.49 at the most recent assessment. It is worth noting that during the preceding trading session, the LIAN stock witnessed a modest decline of 2.11%, ultimately settling at $1.39. This notable upswing in LIAN stock is the result of a noteworthy development – the company’s entrance into a strategic alliance.

    Today, LianBio (LIAN) formalized a significant agreement with Bristol Myers Squibb (BMS). In accordance with the terms of this pact, BMS has been granted exclusive rights by LianBio to spearhead the development and commercialization of mavacamten within the confines of Mainland China, Hong Kong, Macau, Taiwan, Singapore, and Thailand.

    This agreement marks a transition from the exclusive license agreement that LianBio had previously entered into with MyoKardia, Inc., now a wholly-owned subsidiary of BMS, back in August 2020, in pursuit of these very rights. As per the stipulations outlined in the agreement, LIAN is set to receive a one-time payment of $350 million.

    Furthermore, LianBio will be absolved from its financial commitments, which could have amounted to as much as $127.5 million in pending milestone payments under the MyoKardia license agreement. In April 2023, the China National Medical Products Administration (NMPA) accorded Priority Review status to a New Drug Application (NDA) for mavacamten.

    The NDA was intended for the treatment of adults afflicted by symptomatic obstructive hypertrophic cardiomyopathy (oHCM). LianBio had already secured approvals for mavacamten for the treatment of symptomatic oHCM in Macau and Singapore earlier in 2023.

    The LIAN team successfully executed a meticulous clinical development and regulatory strategy within its designated regions, and has judiciously established a robust infrastructure in anticipation of the potential approval of mavacamten in China in the forthcoming year.

    With BMS taking the helm as the global owner, the company is ideally poised to further enhance the value created by LianBio for mavacamten in China and enhance patient access to this vital new therapeutic offering across the specified territories. BMS also has plans to extend employment offers to select LianBio personnel who have been actively engaged in the development and commercialization of mavacamten.

    In tandem with this transaction, the Board of Directors at LianBio has initiated a comprehensive strategic evaluation of the company’s trajectory. The LianBio Board of Directors anticipates furnishing an update on the results of this strategic review in the first half of 2024.

  • A Look At What’s Driving Bridger Aerospace (BAER) Higher Today

    A Look At What’s Driving Bridger Aerospace (BAER) Higher Today

    Bridger Aerospace Group Holdings, Inc. (NASDAQ: BAER) is experiencing a notable upswing in the current session this morning, with a remarkable 18.47% surge, bringing its current value to $4.81 at the last check. The trading volume for Bridger Aerospace stock has far exceeded 400,000 shares, a striking contrast to its average weekly volume of 40,000 shares per day. This surge in BAER stock follows the company’s decisive move to terminate a public offering of its common stock.

    The determination to discontinue the proposed public offering of common stock was prompted by the prevailing market volatility and conditions. This led Bridger Aerospace (BAER) to revoke its prior announcement of a public stock offering made on October 17, 2023. The management at Bridger Aerospace reached the conclusion that the present market conditions do not favor a public offering under terms that would be advantageous for the company and its shareholders.

    Notably, Bridger Aerospace recently emerged victorious in a competitive public tender process to acquire four Canadair CL-215T Amphibious Aircraft from the Spanish Ministry for Ecological Transition and Demographic Challenge. This acquisition elevates Bridger’s Scooper fleet to 10 Scoopers, establishing it as the preeminent private owner of CL-215T/415 Super Scoopers on a global scale.

    Additionally, with the anticipated completion of the acquisition of Bighorn Airways, Inc. in 2023, Bridger Aerospace’s firefighting fleet will encompass an impressive total of 32 aircraft. BAER aspires to have the first two Scooper aircraft ready for deployment in the 2024 fire season, with the additional Scooper aircraft becoming available once the necessary upgrades to their airframes are implemented.

    In accordance with the terms of the tender, Bridger Aerospace is set to acquire the four Scoopers from the Spanish government for €40 million, with the transaction to be executed following the Spanish public tender process. This purchase represents a strategic and transformative milestone for BAER and has far-reaching implications for the global firefighting market, particularly considering the current scarcity of aerial firefighting assets.

  • Why Is LumiraDx (LMDX) Stock Booming Today?

    Why Is LumiraDx (LMDX) Stock Booming Today?

    LumiraDx Limited (NASDAQ: LMDX) is making headlines as its stock experiences a remarkable surge in early trading. LumiraDx stock price has skyrocketed to $0.3059, marking a staggering 251.61% increase from previous levels. Moreover, trading volume of LMDX stock has surged to over 96 million shares, a significant difference from its average daily trading volume of fewer than 300,000 shares. This remarkable uptick in LMDX shares can be attributed to an announcement made by the company regarding a strategic collaboration.

    LumiraDx recently unveiled a groundbreaking partnership with AstraZeneca and Everton in the Community. Together, they aim to establish England’s first community-based heart and lung screening hub, set to become operational in November. This innovative screening facility will be managed by Everton Football Club’s official charity from the newly inaugurated People’s Place.

    The screening hub will offer the Merseyside community access to state-of-the-art technologies and a team of diverse specialists, including primary care, heart, and lung experts. Their collective focus will be on the early detection and treatment of chronic breathlessness in a convenient walk-in setting. Notably, this endeavor represents a pioneering effort in England, offering screenings for heart failure, COPD, and asthma with next-generation diagnostics that eliminate the need for traditional blood draws.

    Artificial intelligence will play a significant role in aiding heart failure detection and reducing associated complications through early intervention. Furthermore, this initiative will raise awareness of conditions causing chronic breathlessness and provide lifestyle assessments and guidance.

    The utilization of LumiraDx’s NT-proBNP test, which requires only a simple fingerstick sample instead of a full blood draw, will make heart health assessments more accessible within the community. This streamlined diagnostic process promises to deliver faster heart failure diagnoses, ultimately leading to improved patient outcomes and more favorable economic outcomes for the National Health Service (NHS).

    In addition to its collaboration with Everton and AstraZeneca, LumiraDx is actively involved in another initiative, the “Your Heart Matters” Bus, in partnership with Medtronic. This program seeks to enhance patient outcomes by expanding access to essential diagnostic tests and transforming the delivery of patient care within the community.

    LumiraDx’s recent endeavors exemplify its commitment to advancing healthcare accessibility and patient care, particularly in the realm of heart and lung health. The company’s innovative approach promises to have a substantial impact on early disease detection and ultimately improve patient outcomes while relieving healthcare burdens.